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Available online 14 March 2016Background: Toll-like receptors (TLRs) are pattern-recognition-receptors that sense a variety of pathogens
and initiation of innate and adaptive immune responses. This studywas undertaken to investigate the expression
of TLRs in peripheral blood-mononuclear cells (PBMCs) of AA patients and to determine whether TLR-mediated
inﬂammatory signals are important for the perspective of AA management.
Methods: Gene expression of TLRs and T-helper (Th) type-1, Th-2, Th-17 and regulatory T-cell cytokines in
PBMCs was quantiﬁed by TaqMan Assays. Production of these cytokines in serum samples was determined by
sandwich ELISAs.
Results: All TLRs (TLRs 1–10)were expressed in PBMCs of AA patients. Importantly intracellular TLRs (TLRs 3, 7, 8
and 9) were signiﬁcantly up-regulated in AA patients as compared with controls (p b 0.05). Interleukin (IL)-2,
TNF-α, and IL-17A gene expression in patients' PBMCs and their secretion in patients' sera were signiﬁcantly
higher as compared with their respective controls (p b 0.05). Whereas, TGF-β gene expression in patients'
PBMCs and TGF-β protein level in patients' sera were signiﬁcantly lower as compared with their controls
(p b 0.05).
Conclusion: This is the ﬁrst report that shows the comprehensive expression proﬁle of TLRs in AA patients. We
conclude that up-regulated expression of intracellular TLRs in PBMCs of AA patients may play an active role in
abnormal regulation of Th-1, Th-17 and regulatory T-cell cytokines in alopecia areata.
General signiﬁcance: Targeting of TLRs and their associated inﬂammatory signaling will open new areas of
research; this may lead to the development of novel therapeutic targets for the treatment of AA or other
skin disorders.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Alopecia areata
Toll-like receptors
IL-2
TNF-α
IL-5
IL-4
IL-17A
TGF-β
Gene expression1. Introduction
Alopecia areata (AA) is a non-scarring, inﬂammatory skin disease
that results in patchy hair loss. AA is unpredictable in its onset, severity,
and durationmaking it potentially very stressful for affected subjects
[1,2]. There are many hypotheses for the etiopathogenesis of AA and
it is probable that it involves several factors ranging from the genetics of
the immune system to autoantigen speciﬁcity and expression patterns
[1–3]. Studies have shown that it is likely that the time of onset and se-
verity of AA are determined by interaction between patient's genetic
predisposition and exposure to environmental triggers [1–3]. Presently,
the hypotheses for AA development mostly focus on the damage ofchemistry, College of Medicine,
Arabia.
ed).
t authors.
. This is an open access article underimmune properties of the hair follicles and the nature of autoimmune
reactions that result in the lymphocytes' subsequent attack [1]. Studies
are being conducted to look for the autoantigens thatmay be associated
with the development of AA but the exact nature of the inciting antigen
epitope(s) remains to be elucidated [1,3]. Now it has been suggested
that a T-cell mediated process is stimulated by endogenous or
exogenous stimuli with the interaction of several molecules [1,4],
where T-helper cells such as Th-1, Th-2 and Th-17 cells and regulatory
T-cells have been implicated [5]. In AA, abnormalities in T-cell-
mediated immunity and cytokine secretion have been well reported
[4–6]. Despite these advancements in modern molecular approaches,
still the treatment options for AA are limited and the efﬁcacy of these
treatments varies from patient to patient and the exact etiology of AA
is still unknown.
Toll-like receptors (TLRs) are key regulators of the innate and
adaptive immune response and are activated by discrete molecular
components of invading pathogens termed pathogen associatedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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TLRs have been reported till date [7]. TLRs are located either at the
cell surface (TLRs 1, 2, 4, 5, 6) or in the intracellular compartment
(TLRs 3, 7, 8, 9) primarily on exosomes and endoplasmic reticulum
[8]. Activation of TLRs initiates a signaling cascade through the
adopter molecules for the induction of variety of cell dependent
responses, including expression and production of various inﬂam-
matory cytokines, phagocytosis, immune cell recruitment and anti-
gen presentation [7]. In AA patients, impaired apoptosis and invalid
cellular debris clearance lead to increased concentration of serum
nuclear and cytoplasmic contents, which are well-known ligands
for TLRs 3, 7, 8 and 9 [10,11]. Dysfunctionality in the expression of
TLRs and their associated effects on the signaling events have been
reported in numerous disorders [12,13] and also in few skin diseases
[14,15] but the role of TLR expression in AA pathogenesis has never
been investigated. Therefore, we hypothesized for the very time
that TLR-mediated inﬂammatory signals contribute to the pathogen-
esis of AA. To investigate this, we evaluated TLR expressions on
PBMCs obtained from AA patients, examined their relations with ex-
pression and production of Th-1, Th-2, Th-17 and regulatory T-cell
cytokines. Our novel results show that gene expression of intracellu-
lar TLRs 3, 7, 8 and 9 were expressed prominently in the PBMCs of AA
patients, whereas expression of cell surface TLRs 1, 2, 4, 5 and 6 were
comparatively low. Moreover, our results also show that Th-1 cyto-
kines IL-2 and TNF-α gene expression in PBMCs and protein produc-
tion in serum samples were signiﬁcantly higher in AA as compared
with healthy controls, whereas no signiﬁcant change was found in
gene expression and protein production of Th-2 cytokines IL-5 or
IL-4 in AA as compared with healthy controls. Gene expression and
protein secretion of Th-17 cytokine IL-17A was found to be higher
in AA as compared with controls humans, whereas regulatory
T-cell cytokine TGF-β was found to be signiﬁcantly lower in AA
patients as compared with healthy controls. Characterization of
TLRs and their role in inﬂammatory signaling events will deﬁnitely
open new areas of research which may lead to the development
of novel therapeutic targets for the treatment of AA or other
skin disorders.Table 1
Characterization of enrolled subjects.
Human subjects Age (years)
mean ± SD.
Sex
(M/F)
SALT ≥ 25% SALT b 25%
AA patients
(n = 25)
30.2 ± 8.43 21 M/4F n = 14 n = 18
Healthy controls
(n = 26)
32.8 ± 10.8 21 M/5F – –
AA, alopecia areata; n, number of samples tested; SALT, severity of alopecia tool scores;
M, male; F, female.2. Methods
2.1. Patients' recruitment
Present study has been carried out in accordance with the Code of
Ethics of the World Medical Association (Declaration of Helsinki as
revised in Tokyo 2004) for humans which was approved by the local
ethical committee of College of Medicine, Qassim University, KSA.
Study subjects were recruited through the dermatology outpatient
clinics of Qassim University, Buraidah, KSA and informed consent was
obtained from each subject. Patients were classiﬁed according to
Alopecia Areata Foundation Clinical Assessment Guidelines [16]. The
study group included 25 AA patients with patchy persistent (4 females
and 21males) and their age rangewas 19–43 years (mean±SD, 30.2±
8.43 years). The severity of the disease was determined using the
Severity of Alopecia Toll (SALT) scores and the patients were divided
into the following two groups based on the higher versus lower SALT
scores: (1) SALT ≥ 25% and (2) SALT b 25%. Venous blood samples
from the patients were collected at the time of joining the clinics.
Patients did not receive any systemic or topical drug therapy for the
last three months, did not have any additional systemic disease, had
no history of systemic medication use, and had no smoking and the
regular exercising habits except their daily activities. The control
group comprised 26 healthy subjects (5 females and 21 males, age
range 20–48 years, mean ± SD age 32.3 ± 10.8 years). The mean ages
were not signiﬁcantly different between the groups. The racial/ethnic
and sex compositions of the AA groups were comparable with those ofthe control group. The demographic and SALT details of patients are
summarized in Table 1.
2.2. Preparation of peripheral blood mononuclear cells
Venous blood samples from the control subjects and AA patients
were collected during routine laboratory examination. PBMCswere iso-
lated by gradient centrifugation using Histopaque-1077 (cat. # 10,771,
Sigma-Aldrich Inc., St. Louis, MO, USA) according to the manufacturer's
instruction. Brieﬂy, freshly collected blood was precisely applied on the
surface of the gradient and centrifuged at 1600rpm for 20 min. The
obtained buffy coat at the interphase was collected and dispersed in
5 ml of Hank's medium (cat. # H4641, Sigma-Aldrich) and centrifuged
at 1600rpm for 10 min. The supernatant was collected and cells
were washed twice with RPMI 1640 medium (cat # SLM-140-B,
Millipore, USA) at 1100 rpm for 5 min each time. The PBMCs were
then dispersed in phosphate buffered saline (PBS, cat # SH30258.01,
HyClone Laboratories, Inc., South Logan, Utah).
2.3. Quantitative real time-PCR
Real time quantitative polymerase chain reaction (qRT-PCR)
was used to quantify the expression of mRNA for TLR-1–TLR-10,
IL-2, TNF-α, IL-5, IL-4, IL-17A and TGF-β with expression of endoge-
nous control GAPDH as we described previously [17,18]. Total
RNA was separated from isolated PBMCs by total RNA isolation kit
(catalog # AM1560, Ambion, CA, USA). First strand cDNA was syn-
thesized using 1 μg total RNA and the SuperScript First Strand
cDNA synthesis kit (catalog # 75780, Affymetrix Inc., OH, USA).
Primers used for PCR assisted ampliﬁcation are listed in Table 2.
PCR ampliﬁcation was carried out using the core kit for SYBR Green
or Taqmann reagent (Applied Biosystem, Foster City, CA) and the
Step One Real Time PCR System (Applied Biosystems). Typical proﬁle
times used were initial step, 95 °C for 10 min, followed by a second
step at 95 °C for 15 s and 60 °C for 60 s for 40 cycles with melting
curve analysis. The level of target mRNA was normalized to the
level of GAPDH and compared to control (untreated sample). Data
was analyzed using ΔΔCT method [19].
2.4. Cytokine ELISA
Levels of IL-2, TNF-α, IL-5, IL-4, IL-17A and TGF-β in the serum
samples of AA patients and normal human controls were quantiﬁed
using commercially available speciﬁc sandwich ELISA kits (GenWay
Biotech, Inc., CA, USA) according to the instructions of themanufacturer.
Plate was read using an automatic microplate reader (Anthos Zenyth
3100 Multimode Detectors, Salzburg, Austria).
2.5. Statistical analysis
All measurements were performed in duplicates and repeated
using PBMCs prepared from AA patients and normal human controls.
Statistical comparisons were performed by One-way ANOVA analysis
followed by Tukey's post-hoc analysis or Two-way ANOVA followed
Table 2
Details of primers used in gene expression studies.
Gene name Accession number Forward primer Reverse primer
TLR-1 NM_003263.3 5′-TGTGCTGCCAATTGCTCATT-3′ 5′-TTTTCCCCATAAGTCTCTCCTAAGAC-3′
TLR-2 NM_003264.3 5′-TCCGTCTTTTTGATGAGAACAATG-3′ 5′-ACTCCAGGTAGGTCTTGGTGTTCA-3′
TLR-3 NM_003265.2 5′-TTTGCGAAGAGGAATGTTTAAATCT-3′ 5′-CACCTATCCGTTCTTTCTGAACTG-3′
TLR-4 NM_138557.2 5′-GAGCCGCTGGTGTATCTTTGA-3′ 5′-CCAGCACGACTGCTCAGAAA-3′
TLR-5 NM_003268.5 5′-CAGCTTTCCTGGCAATTGACT-3′ 5′-CGACATCTTCCCTGGATGCT-3′
TLR-6 NM_ 006,068.4 5′-GGGACTCAGCATGGTAGAAGGTA-3′ 5′-CTCCTGTTACTCTGCAAGCTTTCA-3′
TLR-7 NM_016562.3 5′-TCCTTGTGCGCCGTGTAAA-3′ 5′-GTCAGCGCATCAAAAGCATTT-3′
TLR-8 NM_016610.3 5′-GCTACGGCAGCGGATCTGT-3′ 5′-CCTTCTGCCTTCGGGTTGT-3′
TLR-9 NM_017442.3 5′-GGCAAAGTGGGCGAGATG-3′ 5′-GCTCTGCGTTTTGTCGAAGAC-3′
TLR-10 NM_001017388.2 5′-CCGTGTCAACGAATCATCCA-3′ 5′-CCCACGGCTTGCACTCTCT-3′
IL-2 NM_000586.3 5′-GTCACAAACAGTGCACCTAC-3′ 5′-CCCTGGGTCTTAAGTGAAAG-3′
TNF-α NM_000594.3 5′-GCAGGTCTACTTTGGGATCATTG-3′ 5′-GCGTTTGGGAAGGTTGGA-3′
IL-5 NM_000879.2 5′-TGCCATCCCCACAGAAATTC-3′ 5′-AGAAAGCAGTGCCAAGGTCTCT-3′
IL-4 NM_000589.3 5′-ACTTTGAACAGCCTCACAGAG-3′ 5′-TTGGAGGCAGCAAAGATGTC-3′
IL-17 A NM_002190.2 5′-GGAACGTGGACTACCACATGAA-3′ 5′-GCGCAGGACCAGGATCTCT-3′
TGF-β NM_000660.5 5′-CGCGCATCCTAGACCCTTT-3′ 5′-CTGTGGCAGGTCGGAGAGA-3′
GAPDH NM_002046.5 5′-TCGACAGTCAGCCGCATCTTCTTT-3′ 5′-ACCAAATCCGTTGACTCCGACCTT-3′
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CA, USA) and p b 0.05 was considered signiﬁcant. Values shown are
mean ± SEM unless stated otherwise.3. Results
3.1. Gene expression proﬁling of Toll like receptors in PBMCs of alopecia
areata patients
In an attempt to understand the role of TLRs signaling in the patho-
genesis of AA,we determined the levels of TLR-1 to TLR-10 transcripts in
PBMCs of AA patients and the results were statistically compared with
age- and sex-matched healthy controls. However, study was performed
mainly onmale participants as the number ofmale participantswas sig-
niﬁcantly more compared to female participants (p b 0.001). Therefore,
results mainly devoted for the male AA patients. We determined the
mRNA levels of these TLRs in freshly isolated PBMCs in patients
and healthy controls by the highly sensitive and speciﬁc quantitative
real time-PCR using speciﬁc primer sequences described in Table 2.
As shown in Fig. 1, the intracellular TLR-3, TLR-7, TLR-8, and TLR-9
mRNA levels in PBMCs of AA patients were signiﬁcantly higher than
those of the healthy controls (p b 0.05). However, the differences
in the mRNA levels of other TLRs (TLR-1, TLR-2, TLR-4, ILR-5, TLR-6,Fig. 1. Gene expression proﬁling of Toll like receptors in peripheral blood mononuclear cells of
RT-PCR using comparative ΔΔCTmethod. Assays were performed in duplicates and results are
versus TLR-7 of alopecia areata patients; @p b 0.01 versus TLR-8 of alopecia areata patients; $pIL-10) between the AA patients group and the healthy control group
were not signiﬁcant (p N 0.05).
3.2. Age wise distribution of TLRs on PBMCs of alopecia areata patients
To determine whether age of the patients plays a role on gene
expression proﬁling of TLRs in AA, patients and normal humans were
divided into two age groups: (i) low age group (age b 20 years)
(n = 12) and (ii) high age group (age ≥ 20 years) (n = 13) and the
mRNA expression of all studied TLRs were estimated by real time
PCR using GAPDH as an endogenous control. As shown in Figs. 2 and
3, age-dependent increase was observed in the mRNA expression of
TLR-3 (p b 0.01), TLR-7 (p b 0.001), TLR-8 (p b 0.001) and TLR-9
(p b 0.05), whereas other TLRs showed no age-dependent alterations
in their gene expression levels in PBMCs of AA patients (p N 0.05).
3.3. Gene expression of T-helper and regulatory T-cell cytokines in PBMCs of
alopecia areata patients
To validate our hypothesis that dysregulation in the expression of
TLRs may be involved in the expression/production of cytokines in
AA patients, we assessed mRNA expression levels of Th-1 cytokine
(IL-2, TNF-α), Th-2 cytokine (IL-5, IL-4), Th-17 cytokine (IL-17A)alopecia areata patients. The mRNA expressions of TLRs were determined by quantitative
presented asMean± SEM. *p b 0.0001 versus TLR-3 of alopecia areata patients; #p b 0.001
b 0.01 versus TLR-9 of alopecia areata patients.
Fig. 2. Age wise distribution of Toll like receptors (TLR-1–TLR-6) mRNA expression in peripheral blood mononuclear cells of alopecia areata patients. The mRNA expression of TLR-1
(A), TLR-2 (B), TLR-3 (C), TLR-4 (D), TLR-5 (E) and TLR-6 (F) were determined by quantitative RT-PCR using GAPDH as an endogenous control. LA group represents low age group
(age b 20 years), whereas HA group represents high age group (age ≥ 20 years). AAP, alopecia areata patients; NHS, normal human subjects. Assays were performed in duplicates and
results are presented as mean ± SEM. #p b 0.001 versus AAP of LA group.
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healthy controls and their results were compared. Our quantitative
RT-PCR results showed that mRNA levels of IL-2 and TNF-α in
patients with AA were signiﬁcantly higher than those in healthy
controls (Fig. 4A & B; p b 0.05), whereas IL-5 and IL-4 mRNA levels
in AA patients were found to be almost similar as of healthy controls
(Fig. 4C & D; p N 0.05). Moreover, themRNA levels of IL-17A in PBMCs
of AA patients were signiﬁcantly higher than those in PBMCs of
healthy controls (Fig. 4E; p N 0.05). Furthermore, the mRNA levels
of T-cell regulatory TGF-β in PBMCs of AA patients were found to
be signiﬁcantly lower as compared with the levels of TGF-β in
PBMCs from healthy controls (Fig. 4F; p N 0.05).
3.4. Levels of T-helper and regulatory T-cell cytokines in serum samples of
alopecia areata patients
To provide further support to our hypothesis and to assess the con-
tribution of T-helper and regulatory T-cell cytokines in the pathogenesisof AA, we determined the serum levels of IL-2, TNF-α, IL-5, IL-4, IL-17A
and TGF-β in patients with AA (n=25) and their levelswere compared
with their respective healthy controls (n=26). As shown in Fig. 5A, the
serum levels of IL-2 were signiﬁcantly higher in AA patients as com-
pared with their respective healthy controls (p b 0.05). The average
(±SEM) of IL-2 levels in AA patients' sera and control human sera
were 33.2 ± 9.11 and 19.4 ± 5.16 pg/ml, respectively. Similarly, the
levels of TNF-α were determined and were found to be signiﬁcantly
higher in AA patients as compared with healthy controls (p b 0.01).
The average (±SEM) of TNF-α level in AA patients' sera and control
human sera were 27.7 ± 2.4 and 14.7 ± 3.28 pg/ml, respectively
(Fig. 5B). Whereas, the level of IL-5 or IL-4 in the serum samples of AA
patients was found to be statistically similar as compared with their
respective healthy controls (p N 0.05). The average (±SEM) of IL-5 in
AA patients' sera and control human sera were 9.10 ± 6.02 and
7.50 ± 4.50 pg/ml, respectively (Fig. 5C), whereas, the average
(±SEM) of IL-4 in AA patients' sera and controls' sera were 12.1 ±
2.51 and 10.3 ± 2.1 pg/ml, respectively (Fig. 5D). However, the serum
Fig. 3. Age-wise distribution of Toll like receptors (TLR-7–TLR-10) mRNA expression in peripheral blood mononuclear cells of alopecia areata patients. The mRNA expression of TLR-7
(A), TLR-8 (B), TLR-9 (C) and TLR-10 (D) were determined by quantitative RT-PCR using GAPDH as an endogenous control. LA group represents low age group (age b 20 years),
whereas HA group represents high age group (age ≥ 20 years). AAP, alopecia areata patients; NHS, normal human subjects. Assays were performed in duplicates and results are
presented as mean ± SEM. #p b 0.001 versus AAP of LA group; @p b 0.001 versus AAP of LA group; $p b 0.05 versus AAP of LA group.
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AA patients (p b 0.05), when compared with controls. The average
(±SEM) of serum levels of IL-17A in AA patients and healthy controls
were 58.2 ± 14.07 and 21.5 ± 16.32 pg/ml, respectively (Fig. 5E).
Interestingly, the serum levels of TGF-β were found to be signiﬁcantly
lower in AA patients in comparison with healthy controls (p b 0.05).
The average (±SEM) TGF-β levels in AA patients and control sera
were 12.51 ± 5.52 and 28.49 ± 4.95 pg/ml, respectively (Fig. 5F).
3.5. The SALT-related changes in the serum levels of T-helper and regulatory
T-cell cytokines in alopecia areata patients
To further validate our ﬁndings, we assessed the changes in serum
levels of T-helper and regulatory T-cell cytokines as a function of
the AA disease severity using SALT scoring system. For that patients
were divided into 2 groups: (i) higher disease severity (SALT ≥ 25%)
(n = 14) and (ii) lower disease severity (SALT b 25%) (n = 18) and
the levels of cytokines were estimated. As shown in Fig. 6A, levels of
IL-2 were signiﬁcantly higher among AA patients, whose SALT scores
were ≥25%when compared with patients of SALT b25% or with healthy
controls (p b 0.05). Importantly, patients with SALT b25% showed no
signiﬁcant change in IL-2 levels, when compared with healthy controls
(p N 0.05). The average (±SEM) IL-2 levels in the patients' sera with
SALT ≥25% and SALT b25% were 36.5 ± 4.5 and 27.5 ± 1.5 pg/ml, re-
spectively (Fig. 6A). Similarly, the levels of TNF-α were determined
and were found to signiﬁcantly higher in patients with SALT ≥25% as
compared to those AA patients with SALT b25% orwith healthy controls
(p b 0.05). The average (±SEM) TNF-α levels in the patients' sera with
SALT ≥25% and SALT b25% were 26.3 ± 2.9 and 17.7 ± 1.9 pg/ml, re-
spectively. Whereas, the average (±SEM) TNF-α level in the controls'
serawas 14.7±3.89 pg/ml (Fig. 6B). To further strengthen our ﬁndings,
we also investigated the levels of IL-5 and IL-4 in these patient groups.
Interestingly, levels of both IL-5 and IL-4 were found to be almost simi-
lar in patientswith SALT ≥25% andwith SALT b25% and also similarwithhealthy controls (p N 0.05) (Fig. 6C & D). In addition, we also demon-
strated the levels of IL-17A in patients with SALT ≥25%, SALT b25%
and in healthy controls. Our data showed that IL-17A levels were signif-
icantly increasedwith the increase of the disease severity (p b 0.05). The
average (±SEM) IL-17A levels in the patients' sera with SALT ≥25%,
SALT b25% groups and healthy controls were 80.5 ± 8.5, 48.1 ± 4.1
and 21.5± 11.5 pg/ml, respectively (Fig. 6E). Furthermore, TGF-β levels
were also determined in the serum samples of these patient groups and
in healthy controls and were found to be signiﬁcantly lower in patients
with SALT ≥25% as compared with patients of SALT b25% or with
healthy controls (p b 0.05). The average (±SEM) TGF-β levels in the
patients sera with SALT ≥25%, SALT b25% groups and healthy controls
were 80.5 ± 8.5, 48.1 ± 4.1 and 21.5 ± 11.5 pg/ml, respectively
(Fig. 6F). Our data pointed out that the levels of TGF-β were decreased
with the increase of disease severity.
4. Discussion
This is the ﬁrst report to the best of our knowledge that shows the
comprehensive characterization of TLR expression in peripheral blood
cells of patients with alopecia areata. TLRs are basically a category of
receptors that recognize and activate their signaling cascades to defend
against the pathogen factors. However, an alteration in the proper
activation might occur, resulting in the production of proinﬂammatory
cytokines [20,21]. These improper activations are responsible for the
beginning of autoimmune diseases. Studies have also shown that the
inhibition of the implicated receptors or their pathways may prevent
the onset of autoimmunity [20]. Activation of TLR signaling cascades
in peripheral blood cells has been studied to regulate the expression
of a range of cytokines [12,21,22]. Since both TLRs and cytokines are
linked to the pathogenesis of AA, therefore it can be hypothesized that
dysregulation in the expression of TLRs and cytokines after improper
activation of TLRs may play an active role in the pathogenesis of AA.
To test this hypothesis, we analyzed the gene expression levels of all
Fig. 4.Gene expression of T-helper and regulatory T-cell cytokines in peripheral bloodmononuclear cells of alopecia areata patients. ThemRNA expressions of (A) IL-2, (B) TNF-α, (C) IL-5,
(D) IL-4, (E) IL-17A and (F) TGF-β in PBMCs from AA patients and healthy controls were determined by quantitative RT-PCR using comparative ΔΔCTmethod. Assays were performed in
duplicates and results are presented as mean ± SEM. *p b 0.01 versus IL-2 mRNA of healthy human controls; †p b 0.01 versus TNF-αmRNA of healthy human controls; ‡p b 0.001 versus
IL-17A mRNA of healthy human controls; §p b 0.01 versus TGF-βmRNA of healthy human controls.
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T-helper (Th) cells type-1, Th-2, Th-17 and regulatory T-cell cytokines in
PBMCs of AA patients and their expression levels were compared with
PBMCs of healthy human controls. Higher gene expression of
intracellular TLRs: TLR-3, TLR-7, TLR-8 and TLR-9 have been found in
AA patients, compared to healthy individuals. However, the gene ex-
pression levels of other TLRs: TLR-1, TLR-2, TLR-4, TLR-5, TLR-6, and
TLR-10 showed insigniﬁcant alterations in AA patients as compared
with healthy individuals.Moreover,we also demonstrated that patients'
ages play a role on the expression of TLR-3, TLR-7, TLR-8 and TLR-9, as
their mRNA levels were found to be higher in patients with higher age
group (age ≥ 20 years) compared to the low aged group patients
(age b 20 years). However other TLR mRNA expression remains
unchanged. Therefore these results may indicate that patients' ages'
may play a role in the activation of TLRs 3, 7, 8, and 9 signaling cascades
in AA patients. As the study wasmainly conducted in male participants,
therefore these results are fully symbolized for male AA patients.
The family of TLRs plays a central role in the cutaneous immune
defense system. To date, different TLRs have been found on cell popula-
tions of skin and blood cells from patients with various dermatological
disorders [23]. In AA, correlation of T-cells and their effector cytokines,
yet remains to be fully investigated but it is suggested that they may
play an active role in the selective loss of hairs [6,24]. In this study, we
determined the gene expression of T-helper type 1 cytokine IL-2 in
PBMCs of AA patients and healthy individuals. Our novel data showed
signiﬁcant increased levels of IL-2 mRNA in AA patients as compared
with healthy controls. To further validate the role of Th-1 cytokines in
AApathogenesis, the level of oneof themostwell-knownTh-1 cytokine,
TNF-α was determined at both gene and protein levels in AA patients.Our data demonstrate higher mRNA levels of TNF-α in PBMCs of
AA and higher TNF-α level in the sera of AA patients as compared
with their respective healthy controls. The elevated levels of IL-2
and TNF-α in patients' PBMCs and in patients' sera clearly indicate
that Th-1 cytokines play an important role in the pathogenesis of
the disease. In this study, when AA patients were divided into 2
groups based of their SALT scores (≥25% versus b25%), patients
with higher SALT scores (SALT ≥25%) showed a remarkable increase
in the serum levels of both IL-2 and TNF-α as compared to the pa-
tients with lower SALT scores (SALT b 25%). These data clearly indi-
cate that Th-1 cytokines in AA patients may play an active role in the
disease progression and in elucidating the mechanisms of disease
pathogenesis.
The role of T-helper type-2 cytokines in AA remains unresolved.
Different research groups showed different observations on the serum
levels of Th-2 cytokines in AA. Therefore the roles of Th-2 cytokines in
AA now become controversial [6,25,26]. To the best of our knowledge,
the present study is the only one that has demonstrated the role of
IL-5 in AA pathogenesis. Our novel data determined mRNA levels of
IL-5 in PBMCs of AA and was found to be almost similar as in PBMCs
from healthy controls and results were the same in the patients' and
controls' sera. It is important to point out that IL-5 is actually not a
representative sole marker for Th-2 cytokines; therefore for further val-
idation of IL-5 results, we also investigate the levels of IL-4, which is a
well-known Th-2 cytokines. Like IL-5, IL-4 also showed similar mRNA
levels in patients' PBMCs and similar levels in the patients' sera as com-
pared with their respective healthy controls. To further validate these
results, we also investigated the levels of IL-5 and IL-4 in patient groups
with different SALT scores. Interestingly, serum levels of both IL-5 and
Fig. 5. Serum levels of T-helper and regulatory T-cell cytokines in alopecia areata patients. (A) IL-2 levels in serum samples of patients with AA and healthy human controls. *p b 0.05
versus controls. (B) TNF-α level in serum samples of patients with AA and controls. ‡p b 0.01 versus controls. (C) IL-5 levels in serum samples of patients with AA and healthy human
controls. IL-5 levels in AA patients versus controls, p N 0.05. (D) IL-4 levels in serum samples of patients with AA and healthy human controls. IL-4 levels in AA patients versus controls,
p N 0.05. (E) IL-17A levels in serum samples of patients with AA and controls. ∥p b 0.01 versus IL-17A serum levels in healthy controls. (F) TGF-β levels in serum samples of patients
with AA and controls. ††p b 0.05 versus TGF-β serum levels in controls. Levels of cytokines in the serum samples were determined by speciﬁc sandwich ELISAs (GenWay). Assays were
performed in triplicates and results are presented as mean ± SEM.
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with SALT b25% and were also similar with healthy controls. In view
of these ﬁndings, we conclude that this subclass of cytokines may not
have their active role in the pathogenesis of AA, but still further studies
are needed to elucidate the detailed mechanistic role in AA. T-helper 17
cells are a distinct subset of T helper cells and their function is mainly
mediated by the production of the proinﬂammatory cytokine IL-17.
The role of Th-17 cells has been implicated in the pathogenesis of vari-
ous autoimmune disorders including animal model [27], but it remains
to be identiﬁedwhether the Th-17 cells play a protective or harmful role
in the host immune system. The detailed participation of Th-17 cells in
the pathogenesis of AA is still unknown. This study demonstrates higher
mRNA levels of IL-17A in PBMCs of AA and higher IL-17A levels in the
sera of AA patients as compared with their respective healthy controls,
indicating that IL-17A may play a role in the pathogenesis of AA. Not
only these, we also provide evidences that serum level of IL-17A in AA
patients was signiﬁcantly increased with the increase of SALT scores
as IL-17A: healthy controls b severe (SALT ≥ 25%) patients b mild
(SALT b 25%) patients. The increased levels of IL-17A observed in AA
patients in the present study provide solid evidence of the involvement
of Th-17 cells in the progress of AA. Importantly the increased levels
of IL-17A in AA patients, together with signiﬁcant increases in Th-1
cytokines, IL-2 and TNF-α provide further evidences for the view that
AA pathogenesis has a dominant Th-1-mediated component, with
potential involvement of Th-17 pathways. However, a fully integratedview of intersecting cytokine networks that support the autoimmune
response in AA is still lacking. Regulatory T-cells are specialized subpop-
ulation of T-cells that play a central role in protection from the onset of
autoimmune disorders by inhibiting the responses of different lympho-
cytes and natural killer cells [6,28]. In this study, we demonstrated
the lower levels of TGF-β gene expression in PBMCs and sera of AA
patients as compared with their respective healthy controls. Moreover,
our results also provide evidences that TGF-β serum level was signiﬁ-
cantly decreased with the increase of AA activity. AA patients with
SALT scores ≥25% showed signiﬁcantly lower TGF-β level as compared
to those patients, whose SALT scores were b25%. Furthermore, patients
with SALT b25% showed lower level of TGF-β as compared with the
healthy controls. These data clearly indicating dysfunctionality of
regulatory T-cells in AA and this may be a reason of the development
of autoimmunity in AA patients. However, the study of T-cell subsets
and associated cytokines is essential to develop a better understanding
of the autoimmune nature of AA. Our ﬁndings in this study strongly
suggest that functional response of intracellular TLRs 3, 7, 8 and 9 may
be involved in the regulation of Th-1, Th-17 cytokines and regulatory
T-cell cytokines in AA patients. However, this study has a few
limitations; the most obvious limitation of the study is the sample size
and region of sample collection. It would have been better to include
50–75 patients, and not to conﬁne the sample collection to only one
region. In addition, study on more female AA patients would further
strengthen our ﬁndings.
Fig. 6. SALT-related alterations in serum levels of T-helper and regulatory T-cell cytokines in alopecia areata patients. (A) Serum levels of IL-2 in AA patients with severity of alopecia tool
(SALT) score ≥ 25% and thosewith SALT score b 25% comparedwith normal human controls. †p b 0.05 versus controls. (B) Serum levels of TNF-α in AA patients with SALT score ≥ 25% and
those with SALT score b 25% compared with controls. §p b 0.05 versus controls. (C) Serum levels of IL-5 in AA patients with SALT ≥25% and those with SALT score b 25% compared with
controls. (D) Serum levels of IL-4 in AA patients with SALT ≥25% and thosewith SALT score b 25% comparedwith controls. (E) Serum levels of IL-17 A in AA patients with SALT score ≥ 25%
and with SALT score b 25% compared to controls. ¶p b 0.05 versus SALT b 25%, ¶p b 0.001 versus controls, ⁎⁎p b 0.05 versus controls. (F) Serum levels of TGF-β in AA patients with SALT
score ≥ 25% and with SALT score b 25% compared to controls. ‡‡p b 0.05 versus SALT b 25%, ‡‡p b 0.01 versus controls, §§p b 0.05 versus controls. Levels of cytokines in the serum
samples were determined by speciﬁc sandwich ELISAs (GenWay). Assays were performed in triplicates and results are presented as mean ± SEM.
141A.A. Alzolibani et al. / BBA Clinical 5 (2016) 134–1425. Conclusions
This is the ﬁrst report that shows the comprehensive expression
proﬁles of all ten Toll-like receptors in the peripheral blood cells of
alopecia areata. Our novel data conclude that all intracellular TLRs:
TLR-3, TLR-7, TLR-8 and TLR-9 are overexpressed in PBMCs of AA pa-
tients. Our results support an idea that unregulated expression of
TLR-3, TLR-7, TLR-8 and TLR-9 in peripheral blood cells of AA patients
may be involved in their signaling cascade to dysregulation of Th-1,
Th-17 and regulatory T-cell cytokines. Moreover, study also sug-
gested that these TLRs can be targeted for the development of
novel treatment regimens for better management of alopecia areata
patients. Even so, more targeted studies concerning the biology and
function of TLRs are warranted and may lead to the development of
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